Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Subscribe To Our Newsletter & Stay Updated
